Scientists at UCSF identified a key cellular switch that plays a large role in pulmonary fibrosis, and found a way of ...
An alliance of scientists at the Broad Institute and Bayer Pharmaceuticals have developed a drug candidate, sevabertinib, ...
Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...
Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to ...
Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to ...
Clinical Trials Arena on MSN
Gyre completes Phase III Pirfenidone trial enrolment for pneumoconiosis
Gyre Pharmaceuticals has completed participant enrolment for its 52-week Phase III clinical trial assessing Pirfenidone ...
Airways dysanapsis, a mismatch between airway calibre and lung volume, has long been observed as a physiological variant ...
A new study finds that EULAR/ACR criteria identify more systemic lupus erythematosus cases among patients with interstitial ...
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...
Severe lung inflammation has been linked to symptoms resembling post-traumatic stress disorder in mice, which could help us ...
Hundreds of workers who have developed lung diseases have had their cases recorded on Queensland's Notifiable Dust Lung Disease Register in the past year. Of the 292 workers with cases recorded, six ...
A phase 3 trial of aTyr Pharma’s efzofitimod in a lung disease has missed its primary endpoint. With a multibillion-dollar market in its sights, the biotech is planning to talk to the FDA about a path ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback